

U.S. Food and Drug Administration

Part 15 Hearing - November 4, 2019

Use of Fecal Microbiota for Transplantation to Treat *Clostridium difficile*

8:00 – 9:00 am	Registration
9:00 – 9:10 am	FDA Opening Remarks
9:10 – 9:20 am	Introductory/Logistics Remarks Theresa Finn, PhD, Associate Director for Regulatory Policy Office of Vaccines Research and Review Center for Biologics Evaluation and Research
	Industry
9:20 – 9:30 am	Carolyn Edelstein, OpenBiome <i>Clinical Evidence of Effectiveness, Safety Evaluation, Impact of FDA's Current Enforcement Policy on FMT Product Development</i>
9:30 – 9:40 am	Kevin Horgan, MD, Seres Therapeutics, Inc., <i>Future and Path Forward</i>
9:40 – 9:50 am	Lee Jones, Rebiotix/Ferring, <i>Impact of FDA's Current Enforcement Policy on FMT Product Development</i>
9:50 – 10:00 am	Paul Kim, Foley Hoag LLP; Microbiome Therapeutics Innovation Group <i>Safety Evaluation, Impact of FDA's Current Enforcement Policy on FMT Product Development, Future and Path Forward</i>
10:00 – 10:10 am	Mark Smith, PhD, Finch Therapeutics Group <i>Impact of FDA's Current Enforcement Policy on FMT Product Development, Future and Path Forward</i>
	Academia
10:10 – 10:20 am	Herbert DuPont, MD, UT Health, Houston/Kelsey Research Foundation <i>Clinical Evidence of Effectiveness, Safety Evaluation, Impact of FDA's Current Enforcement Policy on FMT Product Development</i>
10:20 – 10:30 am	Diane Hoffman, University of Maryland Carey School of Law <i>Safety Evaluation, Future and Path Forward</i>
10:30 – 10:40 am	Amanda Kabage, University of Minnesota, <i>Future and Path Forward</i>
10:40 – 10:50 am	Norman Javitt, MD, NYU Langone, <i>Clinical Evidence of Effectiveness</i>
10:50 – 11:10 am	Break

Clinicians

- 11:10 – 11:20 am** Stacey Kahn, MD, Boston Children’s Hospital
Clinical Evidence of Effectiveness, Safety Evaluation
- 11:20 – 11:30 am** Colleen Kelly, MD, American Gastroenterological Association
Clinical Evidence of Effectiveness, Safety Evaluation, Future and Path Forward
- 11:30 – 11:40 am** Sahil Khanna, Mayo Clinic, *Clinical Evidence of Effectiveness, Future and Path Forward*
- 11:40 – 11:50 am** Colleen Kraft, MD, Emory University Hospital, *Future and Path Forward*

Patients

- 11:50 – Noon** Christian Lillis, Peggy Lillis Foundation, *Future and Path Forward*
- Noon – 12:10 pm** Catherine Williams (Duff), *Future and Path Forward*

12:10 – 12:30 pm **Closing Remarks**

We often receive requests for presentations after our public meetings. Due to resource limitations, we are unable to post the presentations to our website.

However, information that is not available on our website may be requested through a Freedom of Information Act (FOIA) request. Information for submitting a FOIA request is located on FDA’s Freedom of Information webpage <https://www.fda.gov/regulatory-information/freedom-information>. This page contains links such as, the Electronic Reading Room, How to Make a FOIA Request, and submitting a FOIA request online.

Please be as specific as possible in your request. Our Access Litigation and Freedom of Information Branch (ALFOIB) will contact you after you submit the FOIA request if additional information is needed.